HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts AstraZeneca (AZN) Investors of Securities Fraud Case Related to Potential COVID-19 Treatment Filed, Filing Deadline Approaching
AstraZeneca PLC (AZN) Securities Fraud Class Action : The complaint alleges that Defendants misrepresented and omitted to disclose widespread flaws in the design, execution, and results of the company's clinical trials of AstraZeneca's COVID-19 vaccine candidate (AZD1222). Specifically, Defendants concealed that: (1) a critical manufacturing error resulted in a substantial number of trial participants receiving half the designed dosage; (2) clinical trials consisted of an improper patient makeup that received subtly different treatments undermining any conclusion that could be drawn from th...